The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17

Late-breaking session featuring data from ORION-1 study to be webcast simultaneously with presentation at 1:30 p.m. on March 17, 2017

New Time for Conference Call – Previously-scheduled conference call/webcast to review data from ORION-1 moved to 4:30 p.m. on March 17, 2017

The Medicines Company (NASDAQ: MDCO) today announced that it will webcast, over the internet simultaneously with the presentation, the detailed results from its ORION-1 Phase II study of inclisiran, the Company’s PCSK9 synthesis inhibitor, featured in the “Late-Breaking Clinical Trials - Featured Clinical Research 1” session at the American College of Cardiology’s 66th Annual Scientific Session on Friday, March 17, 2017, at 1:30 p.m., Eastern Time.

In addition, in order to ensure the availability of key outside experts, The Medicines Company has moved the time of its previously-scheduled conference call and webcast to review data from the ORION-1 study to 4:30 p.m., Eastern Time, on Friday, March 17, 2017. Among those joining the Company’s management and inclisiran product teams for the conference call will be ORION-1’s principal investigator, Kausik K. Ray, M.D., MPhil (Cantab), FRCP, Professor of Public Health, Imperial College London, as well as John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam.

Webcast Information for Late-Breaking Clinical Trial Presentations

Live audio and video of the “Late-Breaking Clinical Trials - Featured Clinical Research 1” presentation by ORION-1’s principal investigator, Kausik K. Ray, M.D., MPhil (Cantab), FRCP, Professor of Public Health, Imperial College London, will be webcast over the internet at 1:30 p.m., Eastern Time. The live webcast may be accessed from the “Investors-Events/Presentations” section of The Medicines Company website.

Investor Conference Call and Webcast Details

The 4:30 p.m. investor conference call may be accessed as follows:

U.S./Canada: [phone]|International: [phone]Conference ID: 60380330

The live webcast may be accessed in the “Investors-Events/Presentations” section of The Medicines Company website.

A taped replay of the conference call will be archived and available for approximately one week. The replay may be accessed as follows:

U.S./Canada: [phone]International: [phone]Conference ID: 60380330

A replay of the webcast will also be archived and available after the conference call.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. The Company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005742/en/

MediaMeg Langan, 973-290-6319Vice [e-mail] RelationsKrishna Gorti, M.D., 973-290-6122Vice President, Investor [e-mail]